Characterization of somatomedin/insulin-like growth factor receptors and correlation with biologic action in cultured neonatal rat astroglial cells by Han, V. K.M. et al.
The Journal of Neuroscience, February 1987, 7(2): 501-511 
Characterization of Somatomedin/lnsulin-like Growth Factor 
Receptors and Correlation with Biologic Action in Cultured Neonatal 
Rat Astroglial Cells 
Victor K. M. Han,’ Jean M. Lauder,* and A. Joseph D’Ercolel 
Departments of ‘Pediatrics and *Anatomy, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, 
North Carolina 27514 
The role of somatomedin/insulin-like growth factors (Sml 
IGFs) in neural growth and development is not clearly de- 
fined. To characterize Sm/lGF receptors and to correlate 
binding with the biologic actions of Sm/lGFs in a homoge- 
neous population of neural cells, we isolated and studied a 
nearly pure population of cultured astroglial monolayers de- 
rived from cerebral cortices of neonatal rats. Binding of ra- 
diolabeled Sm/lGFs was specific, saturable, and reversible, 
with 90% of the binding occurring within 6 hr of incubation 
at 4°C. Competitive binding studies with Sm-C/IGF I yielded 
curvilinear Scatchard plots, while studies with IGF II and 
multiplication stimulating activity (WA) yielded linear plots, 
suggesting that 1251-Sm-C/IGF I binds to more than 1 recep- 
tor species, and 1251-IGF II and Y-MSA bind to one only. 
These findings were supported by affinity-labeling studies 
with radiolabeled Sm/lGFs using disuccinimidyl suberate as 
a cross-linking agent. Sm-WIGF I appeared to bind to both 
type I and II Sm/lGF receptors, because cross-linked Y- 
Sm-C/IGF l-receptor complexes with molecular weight (Mr) 
of >300,000 (300K) and 130K (type I receptor) were ob- 
served under nonreducing and reducing conditions, respec- 
tively, as were 220 and 260K complexes (type II receptor) 
under the same respective conditions. 1*51-IGF II and ‘W 
MSA, however, bound only to the M, 220 and 260K moieties 
under nonreducing and reducing conditions, respectively, 
suggesting that these peptides bind only to the type II re- 
ceptor. Competitive binding studies of the cross-linked 
moieties were consistent with this interpretation. In con- 
trast, 1251-insulin bound poorly to astroglia (~0.5% specific 
binding), and cross-linking studies could not definitely dis- 
tinguish among low-affinity binding to the type I Sm/lGF re- 
ceptor, binding to a paucity of insulin receptors, or both. In 
addition, by combining autoradiography to localize 1251-Sm/ 
IGFs binding on astroglial cells and immunocytochemistry 
with anti-glial fibrillary acidic protein to identify the cell type, 
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we have demonstrated cell-surface binding and apparent 
internalization of radiolabeled Sm/lGFs. Concurrent studies 
of Sm/lGF stimulation of 3H-thymidine incorporation re- 
vealed that these cells were most sensitive to Sm-WIGF I, 
followed by IGF II and MSA, and insulin. MSA and IGF II, 
however, were the most potent followed by Sm-WIGF I and 
then insulin. Half-maximal stimulations of 3H-thymidine in- 
corporation corresponded closely with half-maximal binding 
displacement for Sm-CYGF I and less so for IGF II and MSA. 
These findings suggest that the mitogenic action of Sm/ 
IGFs is mediated by Sm/lGF receptors and that both recep- 
tor types may be responsible for this effect. Our findings 
strongly support a biologic role for Sm/lGFs in the growth 
of developing astroglial cells that is mediated by specific 
receptors. 
Somatomedins or insulin-like growth factors (Sm/IGFs) are 
polypeptide mitogens with amino acid sequences homologous 
to the A and B portions of proinsulin (for reviews, see Van Wyk, 
1984, and Zapf et al., 1984). Two forms of Sm/IGFs have been 
purified from human plasma: somatomedin-C or insulin-like 
growth factor I (Sm-C/IGF I) (Humbel, 1983; Klapper et al., 
1983), a basic peptide that is growth hormone dependent and 
generally believed to mediate the growth-promoting properties 
of the latter, and insulin-like growth factor II (IGF II), a neutral 
peptide that is less growth hormone dependent (Rinderknecht 
and Humbel, 1978). In rats, homologs of Sm-C/IGF I (Rubin 
et al., 1982) and IGF II [also known as multiplication stimu- 
lating activity (MSA)] (Dulak and Temin, 1973; Moses et al., 
1980; Marquardt et al., 198 1) have been identified. 
The role of Sm-C/IGF I in postnatal growth is well established 
and both Sm/IGFs have been postulated to have a role in em- 
bryonic and fetal growth (Underwood and D’Ercole, 1984). A 
role for Sm/IGFs in growth and development of neural tissues 
has also been suggested. Sara et al. (198 1) postulated that a form 
of somatomedin (termed human embryonic somatomedin) 
stimulates growth of human fetal brain cells in vitro and showed 
that both fetal and adult human brain tissue contains receptors 
to Sm/IGFs (Sara et al., 1982, 1983). Synthesis of Sm/IGFs by 
cultured brain cells has been demonstrated (Binoux et al., 198 1; 
Birch et al., 1984) and cultured neural tissues can respond to 
Sm/IGFs (Westermark and Wasteson, 1975; Lenoir and Ho- 
negger, 1983; McMorris et al., 1986). More recent studies have 
shown that IGF II can be detected in human cerebrospinal fluid 
(Haselbacher and Humbel, 1982) and brain tissues (Haselbacher 
et al., 1985). In addition, very high levels of IGF II have been 
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found in the brain of a newborn with megaencephaly (Schoenle 
et al., 1985). 
In order to study the role of Sm/IGFs in the growth of a 
homogeneous population of defined neural cells, we have uti- 
lized techniaues to senarate neuronal and alial elements, and 
have performed detailed studies of Sm/IGF receptors and bi- 
ologic actions in a homogeneous population of polygonal as- 
troglial cells cultured and “purified” from neonatal rat cerebral 
cortices. Our findings demonstrate that these cells possess high- 
affinity receptors for both Sm-CYIGF I (type I Sm/IGF receptor) 
and IGF II (type II Sm/IGF receptor) and suggest hat each 
receptor can mediate a mitogenic response to these growth fac- 
EDTA solution at room temperature for 30 min. Trypsin activity was 
terminated by the addition of twice the volume of Dulbecco’s modified 
Eagle medium (DME, GIBCO) and 10% FCS. The tissue pieces were 
mechanically triturated and filtered through a 130 PM Nitex monofil- 
ament screen, and the filtrate was centrifuged. The resulting cell pellet 
was gently vortexed, and the cells were resuspended in DME + 10% 
FCSmedium. Viable cell density was determined by trypan blue ex- 
elusion method and then plated in 200 ml tissue culture flasks (Falcon) 
at a cell density of 1 x lo6 live cells/ml (10 ml/flask). The cells were 
cultured at 37°C in 5% CO,/95% air and 1001 humidity. Once confluent, 
the cultures were passed at a dilution of 1:4. The cells were used for 
binding and affinity cross-linking studies between the third and sixth 
passages. Fibroblasts from normal rat kidney (NRK cells, Tissue Culture 
Facility, Lineberger Cancer Research Center, UNC) were cultured and 
studied in an identical manner. 
tors. 
Materials and Methods 
Materials. Sm-C/IGF I was purified as previously described from Cohn 
fraction IV of human plasma (Svoboda et al., 1980). IGF II was isolated 
by isoelectric focusing and high-performance liquid chromatography 
(Svoboda and Van Wyk, 1985), and was judged pure on the basis of a 
single band on SDS-PAGE and lack of ambiguity in the sequence anal- 
ysis of the first 4 amino acids at the NH, terminal end of the molecule 
(M. E. Svoboda, unpublished results). MSA III-2 was a gift of S. Peter 
Nisslev. NCI. and monocomoonent insulin was a gift from Dr. M. Root 
of E. i’llly Co. (Indianapolis, IN). The peptides-were iodinated with 
NaY (New England Nuclear, Boston, MA) according to a modification 
ofthe chloramine-T method (Furlanetto et al., 1977) to a specific activity 
of 150-200 &i/pg. The iodinated Sm-C/IGF I was further purified by 
immunoaffinity chromatography and the other iodinated peptides by 
gel filtration on Sephadex G-50 in 1 M acetic acid as previously described 
(Van Wyk et al., 1980). The iodinated peptides were stored in 1 M acetic 
acid and 3% BSA at -70°C and used for the binding studies within 2 
weeks after iodination. Unlabeled Sm-C/IGF I of at least 90% our&v 
1251-Sm/IGF binding autoradiography. Purified astroglial cells were 
washed once in saline 1 (138 mM NaCl. 5.4 mM KCl. 1.1 mM Na,HPO,. 
1.1 mM KH,PO,, and 22 mM glucose) and treated with 0.1% trypsm 
and 0.02% EDTA solution (5.0 ml/culture flask) at 37°C for 15 min. 
Trypsin activity was then terminated by the addition oftwice the volume 
of complete medium. The cell suspension was triturated and centrifuged, 
and the cell pellet was resuspended in complete medium. Viable cell 
count was performed and appropriate dilutions made to give a final cell 
concentration of 1 x lo4 viable cells/ml. The cell suspension was then 
plated onto 15 mm Thermanox tissue culture coverslips (Lux, Naper- 
ville, IL) in 24 well tissue culture plates (Falcon) in volumes of 0.5 ml/ 
well. The cells were then cultured for 48 hr and changed into serum- 
free medium (BME with penicillin, 5 units/ml, and streptomycin, 5 & 
ml) for another 48 hr prior to the binding studies. 
was used in the competition studies, while less pure preparations were 
used to determine nonspecific binding. 
Astroglial cultures. A pure population of polygonal, flat astroglial cells 
were cultured from neonatal rat cerebral cortices as described by 
McCarthy and de Vellis (1980). Briefly, 1 -d-old Sprague-Dawley rats 
(Charles River Breeding Laboratories, Wilmington, MA) were decapi- 
tated and the brains removed aseptically. The cerebral cortices were 
dissected and the meningeal coverings carefully peeled elf. The cortical 
tissue was cut into small pieces and incubated in 0.1% trypsin and 0.02% 
EDTA solution (GIBCO Laboratories, Grand Island, NY) at room tem- 
perature for 30 min with constant shaking. Trypsin activity was inhib- 
ited by addition of twice the volume of Basal Medium Eagle (BME, 
GIBCO Laboratories) containing 10% fetal calf serum (FCS; Hyclone, 
Sterile Systems Inc., Logan, UT). The cell suspension was removed and 
filtered through a 130 WM nitex monofilament screen (Tetko, Elmsford, 
NY). The remaining tissues were triturated mechanically and filtered; 
the filtrate was combined with the initial cell suspension and was cen- 
The coverslips were washed with 0.1 M HEPES buffer, pH 8.0 (0.1 
M HEPES, 0.12 M NaCl, 5 mM KCl, 1.2 mM MgSO,, 8 mM dextrose, 
and 10 mg/ml BSA) at 4°C. The cells were then incubated at 4°C with 
1251-Sm-C or 1251-IGF II (5 x lo-l2 M in 0.5 ml 0.1 M HEPES buffer) 
with or without an excess of unlabeled peptide for times of 15 min to 
24 hr. To study internalization, incubation was also performed at 22 
and at 37°C for varying lengths of time. At the end of the incubation 
period, binding was terminated by aspirating the incubating medium 
and washing 3 times with cold Hank’s balanced salt solution. The cells 
were then fixed with 4% paraformaldehyde in 70 mM phosphate buffer 
at room temperature for 30 min. The cells were washed with PBS, 
dehydrated through an alcohol series, and then air-dried or immuno- 
stained by either the avidin-biotin technique (Towle et al., 1984) or the 
immunofluorescence technique (McCarthy, 1983), using a primary an- 
tibody against glial fibrillary acid protein (GFAP; Accurate Chemical 
and Scientific Co., Westbury, NY). The coverslips were coated with 
nuclear track emulsion (NTB 2 or 3, Eastman Kodak Co., Rochester, 
NY) and exposed for varying lengths of time at 4°C. The coverslips were 
then developed with Kodak D19 developer diluted 1 : 1 (vol : vol) with 
distilled water, fixed, washed thoroughly, counterstained with methyl 
green pyronin or toluidine blue, dehydrated through ascending alcohol 
series and xylene, mounted with Permount (Fisher), and coverslipped. 
subplated into 48 well tissue culture plates (Costar, Cambridge, MA, 1 
cm2 arowth area ner well) at 0.4 ml/well (120.000 cells/well). The cells 
Binding studies. A cell suspension of purified astroglial cells was pre- 
pared as above in a final concentration of 3 x lo5 cells/ml and then 
trifuged at 2000 x g. The cell pellet was gently vortexed and resuspended 
streptomycin 5 pg/mli. The number of viable cells was determined by 
the trypan blue exclusion method in a hemacytometer (> 901 viable). 
A cell suspension of 2.5-3 x lo6 live cells/ml was prepared and plated 
in comnlete medium (BME with 10% FCS. oenicillin 5 units/ml. and 
in 200 ml tissue culture flasks (75 cm2 growth area; Falcon, Oxnard, 
CA) in volumes of 10 ml/flask (Cl.4 x 105cellslcm2 growth area) (Trim- 
mer et al., 1984). The cells were cultured at 37°C in 5% CO, and 95% 
air with 100% humidity for 12-14 d until confluence. The cells were 
then shaken at 270 rpm for 18 hr at 37°C and the medium containing 
suspended cells was removed, discarded, and replaced with new com- 
plete medium. The resulting culture consists of more than 95% of po- 
lygonal, flat astroglial cells as confirmed by phase-contrast microscopy 
and positive immunostaining with antibody against glial fibrillary acid 
protein (GFAP; McCarthy and de Vellis, 1980). The remaining ~5% 
of cells consisted of process bearing cells (about half of which were 
astrocytes and half oligodendrocytes) and fibroblasts. The cultures were 
used for the studies within 1 week of “purification” and at least 1 d 
after medium change. 
were-cultured for 48 hr and changed into serum-free medium (BME) 
for 48 hr. Cells from representative wells were brought into suspension 
with trypsin EDTA solution, and viable cell counts performed. 
The plated cells were washed with 0.1 M HEPES buffer with BSA 10 
mg/mlj pH 8.0, and then incubated with 1251-Sm/IGFs or 1251-insulin in 
0.1 ml buffer at 4°C. In the initial binding studies to determine satur- 
ability, 1Z51-Sm-C/IGF I concentrations were varied from 5 x 10-l’ to 
3 x 1O-9 M and incubated for 3 hr. In studies of the time course of 
binding, labeled peptides (50,000 cpm/well, 20 fmol) were added to 
each well and incubated for varying lengths of time from 15 min to 24 
hr. To test the reversibility of binding, the incubating solution was 
aspirated after 4 hr of binding, and an excess of unlabeled peptide (10 
&ml) in HEPES buffer was added. In the competition studies 1z51-Sm/ 
IGF binding was determined in the presence of graded concentrations 
of unlabeled peptides (Sm-C/IGF I, IGF II, MSA, and insulin) at 4°C 
for 6 hr. Nonspecific binding for all the studies was determined as the 
binding in the presence of an excess of unlabeled peptides (10 &ml). 
Binding was terminated by the aspiration of the incubating solution and 
washing the cultures thoroughly with cold PBS 3 times. The cells were 
then solubilized with 0.1 N sodium hydroxide and 1% SDS for 15 min 
at room temperature, the cell lysate transferred to test tubes, and the 
Fibroblast cultures. Fibroblasts were also cultured from the meninges 
of the same neonatal rats used for culture of astroglial cells. Meningeal 
coverings peeled from the cerebral cortices were cut into pieces of ap- 
proximately 1 x 1 mm and incubated in 0.25% trypsin and 0.02% 
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Figure 1. Photomicrographs of autoradiographs showing 1Z51-Sm-C/IGF I binding on sparsely plated astroglial cells. Astroglia were immunocy- 
tochemically stained by the avidin-biotin-peroxidase technique with antibody against GFAP. A, Cluster of astroglial cells incubated with lZsI-Sm- 
C/IGF I for 1 hr at 4°C. B, Incubated for 6 hr at 4°C. Incubation for 24 hr at 4°C did not increase the autoradiographic signal significantly. C, 
Incubation for 6 hr at 4°C in the presence of 10 &ml of unlabeled Sm-C/IGF I. D, Incubated for 4 hr at 22°C. Arrows indicate aggregation of 
radiolabel in and around the nuclei, suggesting internalization. E, Higher magnification of a single astroglial cell showing apparent internalization 
of the radiolabel after incubation at 22°C for 4 hr. Arrow indicates aggregation of radiolabel in and around the nucleus. Calibration bar, 50 pm. 
cell associated radioactivity determined in a gamma spectrometer (Hew- 
lett Packard Co., Corvallis, OR). Binding was analyzed by the method 
of Scatchard (1949) according to the “trial and error” technique (Ro- 
senthal, 1967; Pennock, 1973). Using a computer program, several plots 
were generated from the estimated K. and R, (B,,,,,) values for each 
binding site and “goodness” to fit was determined with the observed 
values. 
A#inity cross-linking. A modification of the methods described by 
Wilkins and D’Ercole (1985) and Adams et al. (1983) was used to affinity 
cross-link 1251-Sm/IGFs and 12SI-insulin to receptors on astroglial cells. 
Purified astroglial cells were subplated onto 35 mm tissue culture dishes 
(Falcon) at a cell density of 1 .O x lo6 cells/dish in 2 ml of BME + 10% 
FCS. The cells were arown to confluence. usuallv in 48-72 hr. The 
culture medium was then changed to serum-free BME and then incu- 
bated at 37°C for another 48 hr. The cultures were washed twice with 
0.1 M HEPES buffer. DH 8.0. with BSA 10 ma/ml and incubated with 
*2SI-Sm/IGF or 1251-i&tlin (4-5 x lo5 cpm/dysh) in the same HEPES 
buffer, with or without varying concentrations of unlabeled peptides at 
4°C for 16-l 8 hr. The incubating solution was then aspirated, and cul- 
tures were washed 3 times with cold (4oC) HEPES buffer, pH 7.4, without 
BSA, to remove the unbound radiolabel. 1Z51-Sm-C/IGF I, which was 
bound to surface receptor protein, was affinity cross-linked using the 
cross-linking agent, disuccinimidyl suberate (DSS), in a final concen- 
tration of 0.1 mM by incubation at 22°C for 10 min. The reaction was 
then stopped by aspiration of the DSS solution and addition of 1 ml of 
10 mM Tris HCl. The cells were then scraned from the bottom of the 
dish using a disposable plastic spatula; solubilized in 2% SDS 12.5 mM 
Tris, 0.002% bromophenol blue, and 8% glycerol with or without the 
reducing agent dithiothrietol(lO0 mM); and boiled for 5 min. The pro- 
teins were then separated on a 3-l 4% linear aradient SDS-PAGE usine 
a Tris-glycine buffer, pH 8.0, according to the method described b; 
Laemmli (1970). The gel was then fixed in 101 acetic acid and 30% 
methanol solution, washed, dried, and exposed to an X-ray film (Kodak 
XAR or XRP) between 2 intensifying screens (DuPont) for l-2 weeks. 
The molecular weights of the standards used for SDS-PAGE were myo- 
sin (200,000 Da), phosphorylase-B (97,400 Da), BSA (68,000 Da), oval- 
bumin (43,000 Da), Lu-chymotrypsin (25,700 Da), p-lactglobulin (18,400 
Da), and lysozyme (14,300 Da) (Bethesda Research Laboratories, Be- 
thesda, MD). 
JH-thymidine incorporation studies. To test the mitogenic actions of 
Sm/IGFs and insulin on the astroglial cells, 3H-thymidine (TdR) in- 
corporation studies were performed according to a modification of the 
method described by Russell et al. (1984). The purified astroglial cells 
were treated with 0.1% trypsin and 0.02% EDTA solution, suspended 
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Figure 2. 12SI-Sm-C/IGF I binding to 
astroglial monolayers. Specific binding 
of 1251-Sm-C/IGF I to astroglial mono- 
layers (each point represents the mean 
of 6 replicates) increased as the con- 
centration of radiolabel was increased 
up to 1.5 x 10m9 M. Further increase in 
radiolabel concentration did not in- 
crease specific binding, indicating sat- 
urability of 1251-Sm-C/IGF I binding. 
in BME and 10% FCS medium, and plated onto 48 well tissue culture 
plates (Costar) at a cell density of l-l .2 x lo5 cells/well. The cells were 
cultured at 37°C for 48 hr, following which the medium was changed 
to serum-free BME and incubated for another 48 hr. The cultures were 
then washed with a fresh BME and BSA solution and were then incu- 
bated with varying concentrations of Sm/IGF I, IGF II, MSA 111.2, and 
insulin, while the control cultures were incubated only with BME and 
BSA 2 mg/ml solution. After incubation for 22 hr, ‘H-TdR (0.5 pCi/ 
well) was added to the cultures and the incubation was continued for 
another 2 hr. The reaction was stopped by aspiration of the incubating 
solution and washing with cold (4°C) PBS 3 times. The cultures were 
non-specific 
12 4 6 20 
Time &fours) 
Figure 3. Time course of 1251-Sm-C/IGF I binding to astroglial cells. 
1251-Sm-C/IGF-I, 20 fmol/well, was incubated at 4°C on plated astroglial 
cells and binding terminated at the described time points. Each point 
represents the mean of 6 replicates. Nonspecific binding, determined in 
the presence of an excess of unlabeled Sm-C/IGF I, was 0.8% at 6 hr 
and 1.8% at 20 hr. Specific binding (M) increased rapidly up to 6 
hr, then asymptotically up to 20 hr.. Nonspecific binding in the presence 
of 1 &ml unlabeled Sm-C/IGF I is also shown (W). Reversibil- 
ity of-binding is shown by the 1251-Sm-C/IGF I remaining bound 
(A- A), when fresh medium containing 2 &ml of unlabeled Sm-C/ 
IGF I was added after 4 hr. 
Concentration (nM) 
then incubated with 5% trichloracetic acid (TCA) at 4°C for 20 min, 
the TCA solution aspirated, and cultures washed again with fresh 5% 
TCA. After removal of the TCA solution, the cultures were solubilized 
in 1% SDS and 0.1% sodium hydroxide. The resultant solution was 
added to 10 ml of complete counting cocktail (Research Products In- 
ternational Corp., Elk Grove Village, IL) and counted in a scintillation 
counter (LKB Instruments, Gaithersburg, MD). 
Results 
Autoradiographic studies of 1251-Sm/IGF binding 
Specific binding of 1Z51-Sm-C/IGF by putative cell-surface re- 
ceptors of cultured astroglial cells was shown by association of 
autoradiographic silver grains with sparsely plated astroglial cells 
(Fig. 1, A, B) and the reduction of such signals when the cells 
were incubated in the presence of excess of unlabeled Sm-C/ 
IGF I, 10 &ml (Fig. 1C’). The cells were shown to be astroglia 
by their morphology and positive immunostaining with anti- 
GFAP antibody. Receptor binding autoradiography with other 
radioligands (IZ51-IGF II and IZ51-MSA) gave similar results. 
lZSI-Sm-C/IGF I bound to astroglial cells in a time-dependent 
manner. When incubations were performed at 4°C there was 
an increase in the density of silver grains associated with the 
cells for up to 6 hr (Fig. 1, A, B). No further increase was 
observed when incubation was extended to 24 hr. At 22 and 
37°C an increase in this autoradiographic signal was seen up to 
2 hr of incubation. Within 3 hr, the silver grains appeared to 
accumulate on and around the nuclear region and increased in 
density by 6 hr (Fig. 1, D, E). The latter finding suggests inter- 
nalization of the radiolabeled peptide, a phenomenon known 
to occur with insulin and peptide growth factors (Gorden et al., 
1978; Carpentier et al., 198 1). Positive autoradiography with 
both radiolabeled Sm-C/IGF I and IGF II suggest that astroglia 
possess both receptor subtypes, a finding supported by the cross- 
linking studies (see below). In addition, all the flat, polygonal 
astroglia that were GFAP immunopositive showed binding to 
both radiolabeled peptides. The few process-bearing GFAP- 
positive cells that remained in the cultures also showed binding 
to both ligands. 
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Figure 4. Competition for 12SI-Sm-C/IGF I binding to astroglial cells by unlabeled Sm-CXGF I, IGF II, MSA, and insulin. Binding is expressed 
as the percentage ofmaximum specific binding (10%). Each point is the mean of 3 replicates. The SEM of each data point was less than 5%. Insert 
shows the computer-generated Scatchard analysis of 1251-Sm-C/IGF I binding. For high-affinity binding site, K, = 0.5 x lo9 M-I and R, = 4.5 x 
lo4 receptors/cell; for lower-affinity binding site, K, = 0.05 x lo9 M-’ and R, = 21 x lo4 receptors/cell. 
Quantljcation of 1Z51-Sm/lGF and 12’I-insulin binding 
In order to quantify Sm/IGF receptor binding, studies were 
carried out to allow direct counting of bound radioligand and 
Scatchard analysis. L251-Sm-C/IGF I binding to astroglial cells 
was saturable. When the lz51-Sm-C/IGF I concentration was 
varied from 0.05 to 3.0 nM, specific binding increased expo- 
nentially in concentrations up to 0.6 nM and was maximal at 
1.5 nM (Fig. 2). Specific binding of 1251-Sm-C/IGF I increased 
linearly with time of incubation up to 6 hr, and no further 
increase occurred with time up to 24 hr (Fig. 3). Also, 12sI-Sm- 
C/IGF I binding was reversible (Fig. 3). When the incubating 
solution was removed after 4 hr of incubation, fresh buffer with 
an excess of unlabeled Sm-C/IGF I (10 &ml) added, and the 
radioactivity remaining bound to the cultures measured, the 
cell-associated radioactivity was reduced significantly with sub- 
sequent incubation. Radiolabeled IGF II and MSA demonstrat- 
ed similar specific binding under identical conditions. Radio- 
labeled insulin, however, had specific binding of less than 0.5%; 
therefore, further studies were not performed. 
Scatchard analysis of Sm-C/IGF I binding revealed a curvilinear 
plot that was consistent with the presence of more than 1 class 
of distinct receptors (Fig. 4, insert). Assuming 2 classes of re- 
ceptors, affinity constant (K,) and binding capacity (R,) were 
K, = 0.5 x lo9 M-I, R, = 4.5 x lo4 receptors/cell for the high- 
affinity receptor, and K, = 0.05 x log M-I, R, = 21 x lo4 
receptors/cell for the lower-affinity receptor. 
Competition studies were also performed with 1251-IGF II and 
1251-MSA. The displacement curves of each were similar, with 
unlabeled IGF II and MSA being equipotent and unlabeled SM- 
C/IGF I being about 10 times less potent (Figs. 5,6). Scatchard 
analysis of each yielded nearly linear plots that were virtually 
identical, consistent with a single class of receptors (Figs. 5 and 
6, inserts). The affinity constants (K,) were calculated to be 
0.18 x 109 M-I and 0.2 x lo9 M-I, and the binding capacities 
16.5 x lo4 receptors/cell and 15 x lo4 receptors/cell for 1251- 
IGF II and 1251-MSA, respectively. 
Characterization of Sm/IGF and insulin receptors by afinity 
cross-linking 
To test the specificity of L251-Sm-C/IGF I binding, competition Affinity cross-linking of i251-Sm-C/IGF I to astroglial cell-sur- 
studies were performed with unlabeled Sm-C/IGF I, IGF II, face receptors and analysis on SDS-PAGE under nonreducing 
MSA, and insulin (Fig. 4). Half-maximal displacement of lzsI- conditions showed radiolabeled protein bands with IV, of 220,000 
Sm-C/IGF I binding by unlabeled Sm-C/IGF I and IGF II oc- (220K) andgreater than 300K. These bands were greatly reduced 
curred at 1 x 1O-9 M, while half-maximal displacement was in intensity when incubation was performed in the presence of 
about 1 O-fold less sensitive to unlabeled MSA, occurring at 1 O-8 100 rig/ml unlabeled Sm-C/IGF I (Fig. 7). When SDS-PAGE 
M. Unlabeled insulin, at the highest concentration tested (1 x was performed under reducing conditions, radiolabeled bands 
1O-4 M), could produce only 20% displacement. Despite the of A4,260K and 130K were observed. Both were inhibited by 
sensitivity of l*SI-Sm-C/IGF I binding to competition with IGF coincubation with 100 @ml of unlabeled Sm-C/IGF I. When 
II, 15-20% of this binding was consistently displaced with very incubation was performed in the presence of graded concentra- 
low concentrations of unlabeled Sm-C/IGF I (10-10-10-*4 M). tions of unlabeled Sm/IGFs to assess relative affinity, the in- 
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Figure 5. Competition for Y-IGF II binding to astroglial cells by unlabeled Sm-UIGF I, IGF II, MSA, and insulin. Each point represents the 
mean of 3 replicates. The SEM of each data point was less than 5%. Insert shows Scatchard analysis of 1251-IGF II binding; K. = 0.18 x lo9 M-I 
and R, = 16.5 x lo4 receptors/cell. 
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Figure 6. Competition for lZSI-MSA binding to astroglial cells by unlabeled Sm-C/IGF I, IGF II, MSA, and insulin. Each point is the mean of 3 
replicates. The SEM of each data point was less than 5Oh. Insert shows Scatchard analysis of 1251-MSA binding; K, = 0.2 x lo9 M-I and R, = 
15 x lo4 receptors/cell. 
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tensities of both bands were diminished in the presence of un- 
labeled Sm-C/IGF I, IGF II, or MSA (Fig. 8A; MSA not shown). 
The intensity of the 130K M, band, but not the 260K band, was 
more sensitive to Sm-CYIGF I than to IGF II or MSA and was 
also diminished when the incubation was performed with a high 
concentration of unlabeled insulin (10 &ml). The 130K band 
thus had affinity characteristics of the type I Sm/IGF receptor 
(Pilch and Czech, 1979; Chemausek et al., 1981; Czech, 1982) 
and differed from the 260K M, band. The latter was likely to 
be the type II Sm/IGF receptor because it could be diminished 
in intensity with both Sm-C/IGF I and IGF II but not with high 
concentrations of insulin (10 &ml) (Kasuga et al., 198 1; Mas- 
sague et al., 198 1). The A& > 300K bands observed under non- 
reducing conditions and the M, 130K band observed under 
reducing conditions, therefore, appear to represent the type I 
Sm/IGF receptor, while the M, 220K and 260K bands under 
nonreducing and reducing conditions, respectively, represent 
the type II Sm/IGF receptor (Bhaumick et al., 198 1; Chemausek 
et al., 198 1; Kasuga et al., 198 1). Astroglial cells therefore appear 
to possess both type I and II Sm/IGF receptors, and 1251-Sm-C/ 
IGF I appears capable of binding to both species. 
When lZSI-IGF II was cross-linked to astroglial cells and ana- 
lyzed in SDS-PAGE under nonreducing conditions, the radio- 
label was associated with a protein band of M, 220K (Fig. 7). 
The intensity of this band was greatly diminished when incu- 
bation was performed in the presence of unlabeled IGF II or 
MSA. Under reducing conditions, the radiolabel was associated 
with a protein band of M, 260K, and the capacity of unlabeled 
peptides to obliterate this band was virtually identical to that 
+ 
1 OOng/ml 
Figure 7. Affinity labeling of T-Sm- 
UIGF I (4 lanes at left) and T-IGF II 
(4 lanes at right) bound to astroglial cells 
and analyzed on 3-14% SDS-PAGE 
under nonreducing conditions (DTT -) 
and under reducing conditions (DTT 
+). Specificity of biiding was shown by 
affinity cross-linking in the presence of 
100 r&ml f  14 nM) of resnective unla- 
IGF II beled -peptides as indicated. 
observed under nonreducing conditions. When incubations were 
performed in the presence of varied concentrations of unlabeled 
Sm/IGFs or insulin, and analyzed under reducing conditions 
(Fig. 8B), unlabeled Sm-C/IGF I diminished the intensity of the 
260K band; however, its intensity was not reduced by co-in- 
cubation with unlabeled insulin, even at a concentration of 10 
&ml. Our results further support the conclusion that the pro- 
tein moiety of &.f, 220K observed under nonreducing conditions 
migrates at a higher M, of 260K under reducing conditions and 
is the type II Sm/IGF receptor (Massague et al., 1981). That 
radiolabeled IGF II was not associated with the M, > 300K 
protein bands under nonreducing conditions, or the A4,130,000 
band under reducing conditions, suggests that 1251-IGF II binds 
only to type II Sm/IGF receptors in rat astroglial cells. Identical 
findings were seen when lz51-MSA was affinity cross-linked to 
rat astroglial cells (data not shown). Furthermore, identical ob- 
servations were made when radiolabeled Sm-C/IGF I, IGF II, 
and MSA were affinity cross-linked to meningeal fibroblasts 
derived from neonatal rats and normal rat kidney @IRK) fi- 
broblasts (autoradiograms not shown). These findings suggest 
that IGF II preferentially binds to type II Sm/IGF receptor in 
cells derived from rats. 
When 1251-insulin was affinity cross-linked to astroglial cells 
and analyzed on SDS-PAGE, the radiolabel was preferentially 
associated with M, > 300K of protein bands under nonreducing 
conditions (data not shown) and with M, 260K and 130K pro- 
tein bands under reducing conditions (Fig. 9). The intensities 
of these radiolabeled bands were much less than those seen when 
1251-Sm/IGFs were cross-linked, 3-fold longer exposure times 
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Figure 8. Afhnity labeling of lZSI-Sm-C/IGF I (A) and 1251-IGF II (B) 
bound to astroglial cells in the presence of varying concentrations of 
unlabeled peptides (Sm-UIGF I, IGF II, or insulin) and analyzed on 
3-14% SDS-PAGE under reducing conditions. The key below the panel 
indicates whether unlabeled peptides were present, as well as their iden- 
tity and concentrations (&ml; 100 rig/ml = 14 nM). 
being required for visualization. Because the type I Sm/IGF 
receptor and insulin receptor have similar subunit structure 
(Czech, 1982), size characteristics do not discriminate between 
them, and they must be distinguished on the basis of their rel- 
ative affinities for Sm-C/IGF I and insulin. The intensity of 
these bands was diminished, but not obliterated, in the presence 
of unlabeled insulin, Sm-UIGF I, IGF II, or MSA. Both bands 
appeared to be more sensitive to competition with unlabeled 
Sm-UIGF I or IGF II than with insulin; however, the concen- 
tration of unlabeled Sm-CYIGF I required to obliterate *251- 
insulin binding to the 130K moiety exceeded that required to 
obliterate ‘*4-Sm-C/IGF I binding to the type I Sm/IGF recep- 
tor (500 vs 100 rig/ml). We believe the 260K band represents 
a dimer of 130K subunit, because neither it nor any band less 
than 300K was observed under nonreducing conditions, sug- 
gesting that it is not the type II Sm/IGF receptor. Our findings 
suggest hat lZ51-insulin binds predominantly to type I Sm/IGF 
10 100 100 100 
Unsulin 4 Sm-C IGF II 
rig/ml rig/ml rig/ml 
Figure 9. AlIlnity labeling of 1251-insulin bound to astroglial cells and 
analyzed on 3-14W SDS-PAGE under reducing conditions. The key 
below each lane indicates the nature of competition; insulin, 100 ng/ 
ml = 16 nM; Sm-C/IGF, and IGF I, 100 &ml = 14 nM, respectively. 
receptors. Specific insulin receptors (Razaida et al., 1980) may 
also be present on astroglia, but probably are relatively few in 
number. 
‘H-thymidine incorporation studies 
In order to correlate the receptor binding studies with the bi- 
ologic actions of Sm/IGFs on astroglial cells, TdR incorporation 
studies were performed on cells cultured and plated in an iden- 
tical fashion. DNA synthesis of astroglial cells was stimulated 
by Sm/IGFs and insulin. The maximum TdR incorporation 
response depended on the peptide studied. MSA stimulated the 
greatest response, followed by IGF II, Sm-C/IGF I, and then 
insulin (Fig. lOA). When the same data were plotted as a per- 
centage of the maximal response for each peptide, it appeared 
that astroglial cells were most sensitive to Sm-UIGF I and least 
sensitive to insulin: Half-maximal responses were 0.7 nM for 
Sm-C/IGF I, 6.0 nM for IGF II, 8.0 nM for MSA, and 14 nM 
for insulin (Fig. 1OB). 
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Figure 10. )H-thymidine incorporation of astroglial cells in response to Sm-CXGF I (w), IGF II w, MSA (M), and insulin 
(m). Each point represents the mean of 6 replicate measurements. )H-thymidine incorporation is expressed as the percentage increase above 
control (A) and as the percentage of maximum response (B). A duplicate experiment showed almost identical ‘H-thymidine incorporation responses. 
Maximum responses with IGF II and MSA were achieved with concentrations of 2 x 1O-8 M. Half-maximal responses are as follows: Sm-C/IGF 
I, 0.7 nM; IGF II, 6.0 nM; MSA, 8.0 nM; and insulin, 14 nM. 
Discussion 
As a first step towards defining the role of Sm/IGFs in neural 
development, we have identified and characterized Sm/IGF re- 
ceptors in a pure population of astroglial cells in vitro and pre- 
sented evidence that these receptors mediate the mitogenic re- 
sponse stimulated by these peptides. Astroglial cells were chosen 
to study the role of Sm/IGFs in neural development because 
they are highly proliferative during fetal and neonatal life, sug- 
gesting that they may be capable of proliferation in response to 
potent mitogens such as Sm/IGFs. Because they can be isolated 
and cultured as a relatively homogeneous population (McCarthy 
and de Vellis, 1980), definitive characterization on a single-cell 
population is possible. Receptors for Sm/IGFs have been pre- 
viously identified in neural tissues from various brain regions 
in rats (Lenoir and Honegger, 1983), both fetal and adult (Sara 
et al., 1982, 1984). Because these studies were performed on 
membrane fractions prepared from whole tissues or explant 
cultures, however, the specific neural cells possessing Sm/IGF 
receptors could not be identified. More recently, McMorris et 
al. (1986) have shown that oligodendroglial cells cultured from 
cerebral cortices of rats of similar ages possess receptors for Sm- 
C/IGF I and that these receptors mediate the mitogenic response 
to Sm-UIGF I. 
Our autoradiographic studies of Sm/IGF binding suggested 
that astroglial cells possess Sm/IGF surface receptors. When 
these studies were performed after incubation at 2 1 or 37°C for 
3 hr, radiolabeled Sm/IGFs appeared to be localized in and 
around the nucleus, suggesting internalization. The nucleus may 
therefore be a site of action of these peptides. This finding also 
suggests that Sm/IGFs are internalized and transported to the 
sites of action, similar to insulin (Carpentier et al., 198 1). How- 
ever, confirmation of such a mechanism awaits further inves- 
tigation. 
Competitive binding and affinity cross-linking studies con- 
firmed the autoradiographic studies and extended our charac- 
terization of Sm/IGF receptors. Astroglial cells possess both type 
I and type II Sm/IGF receptors, typical of those defined in other 
cell types (Adams et al., 1983; Kasuga et al., 1981; Massagut 
and Czech, 1982). The fact that L2sI-Sm-C/IGF I can bind to 
both types of receptors was indicated by 2 findings. First, the 
biphasic competition curve showed that a portion of 1251-Sm- 
C/IGF I was extremely sensitive to competition by low con- 
centrations of unlabeled Sm-CXGF I, while higher concentra- 
tions of unlabeled Sm-C/IGF I (identical to those required for 
unlabeled IGF II to compete for Y-Sm-C/IGF I) were necessary 
to compete for the remaining bound peptide; when these data 
were analyzed by the Scatchard method, a curvilinear plot was 
generated, consistent with binding of this peptide to 2 classes 
of receptors. Second, the affinity cross-linking studies showed 
1251-Sm-C/IGF I complexed to protein bands having relative 
competition and size characteristics of both receptor types. Pre- 
viously, 1251-Sm-C/IGF I has been shown to bind to both types 
of Sm/IGF receptors in chick embryo fibroblasts (Adams et al., 
1983). 
Both competitive binding and affinity cross-linking studies 
indicate that insulin binds to the type I Sm/IGF receptor with 
low affinity. i251-Sm-C/IGF I labeling of the M, 130K band 
(under reducing conditions) can be partially displaced by un- 
labeled insulin at very high concentration, but insulin has no 
influence on i251-Sm-C/IGF I binding to the type II Sm/IGF 
receptor (M, 260K under reducing conditions). The latter finding 
was confirmed in both competitive binding and affinity cross- 
linking studies using either 1251-IGF II or ‘251-MSA as radioli- 
gands. Our findings are therefore consistent with those of other 
investigators who have described low-affinity binding of insulin 
to type I Sm/IGF receptor and the absence of binding to the 
type II receptor (Rechler et al., 1976). When 1251-insulin was 
used in binding studies on astroglial cells, less than 0.5% was 
specifically bound. Parallel affinity cross-linking studies were 
consistent with binding predominantly to the type I Sm/IGF 
receptor. Because relatively high concentrations of unlabeled 
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Sm-C/IGF I were incapable of completely inhibiting **SI-insulin, 
however, we cannot exclude the existence of a small number of 
insulin receptors on astroglial cells. Recently, Weyhenmeyer et 
al. (1985) used light- and electron-microscopic immunocyto- 
chemistry with a monoclonal antibody against insulin receptor 
to demonstrate the presence of specific insulin receptors on neu- 
ral cells in culture. Previously, Razaida et al. (1980) showed 
that monolayer cultures of fetal rat brain, composed of neuronal 
and glial cells, possess both high- and low-affinity binding sites 
for insulin. It was postulated that the mitogenic effect of insulin 
was mediated by binding to the low-affinity binding sites. Our 
studies suggest that the low-affinity binding of insulin is likely 
to be to the type I Sm/IGF receptor. Cross-reactivity with the 
type I Sm/IGF receptor could therefore explain the requirement 
of primary and transformed neural cells for high concentrations 
(S-10 &ml) of insulin (Bottenstein, 1984). Support for this 
hypothesis is provided by the finding that the thymidine incor- 
poration dose response to insulin parallels that of Sm-C/IGF I 
at higher concentrations. 
lZ51-IGF II and 1251-MSA demonstrated almost identical bind- 
ing characteristics on astroglial cells, both in competitive bind- 
ing studies and in the affinity cross-linking studies. Both lZ51- 
IGF II and lZ51-MSA appear to bind exclusively to the type II 
Sm/IGF receptors: (1) Competition studies with each radioli- 
gand were essentially identical whether unlabeled IGF II or MSA 
was used for displacement; likewise, they yielded nearly iden- 
tical Scatchard plots with similar affinity constants and receptor 
numbers. (2) Affinity cross-linking studies showed both ‘251-IGF 
II and 1251-MSA to be associated with protein bands having 
competition and size characteristics of type II Sm/IGF receptor. 
These findings are not unusual for cultured cells of rat origin 
because when affinity cross-linking studies were performed with 
cultured fibroblasts from neonatal rat meninges and from kidney 
of normal rats, we could demonstrate only binding of lZ51-IGF 
II and 1251-MSA to the type II Sm/IGF receptor. Similar results 
have been reported for 1*51-MSA binding to chick embryo fi- 
brobiasts (Adams et al., 1983) and lZ51-IGF II binding to rat 
placental membranes (Pilistine et al., 1984). Because IGF II and 
MSA share 93% homology, binding to the same receptors was 
anticipated. In man, however, ‘2sI-IGF II also appears to bind 
the type I receptor of cultured fibroblasts (Massague and Czech, 
1982) and placenta membranes (Casella et al., 1986). The reason 
for these apparent species differences are not clear. 
As demonstrated by our TdR incorporation studies, astroglial 
cells are stimulated to undergo DNA synthesis in response to 
Sm/IGFs and insulin. We believe that we can relate receptor 
binding to biologic action with some degree of reliability, be- 
cause unlike previous reports (Adams et al., 1983; Lenoir and 
Honegger, 1983), we assessed both binding and thymidine up- 
take in monolayer cultures under similar conditions. Half-max- 
imal binding displacement and stimulation of thymidine in- 
corporation by each Sm/IGF were on the same order of 
magnitude, suggesting that the receptors we identified mediate 
the mitogenic response. Our results do not, however, indicate 
with certainty whether both or only 1 of the receptors (type I 
or II) mediates the biologic action. The type I receptor appears 
to mediate Sm-C/IGF I action, because the half-maximal bind- 
ing of Sm-C/IGF I to its high-affinity receptor (presumably the 
type I receptor) and its half-maximal mitogenic response are 
nearly identical (1 .O and 0.7 nM, respectively). However, affin- 
ity-labeling studies showed that 1251-Sm-C/IGF I bound to both 
type I and type II receptors; therefore, our findings do not ex- 
clude the possibility that the mitogenic action Sm-C/IGF I is 
mediated in part by the type II receptor. With IGF II and MSA, 
the half-maximal binding displacement (1 .O nM for each) and 
thymidine incorporation responses (6.0 and 8.0 nM, respective- 
ly) do not correspond precisely, these results suggest that binding 
to the type I receptor could be responsible for the mitogenic 
effect of these peptides. On the other hand, Scatchard analysis 
of both IGF II and MSA binding indicated a single class of 
receptors, and affinity-labeling studies were consistent with this, 
showing cross-linking only to type II receptors. Taken together, 
it is difficult to exclude a biologic role for the type II receptor. 
Czech et al. (1985) have proposed that the type II receptor does 
not mediate biologic responses and that type I receptor, rather 
than the type II receptor, mediates the effects of Sm/IGFs. Other 
data from different cells are also inconsistent with this hypoth- 
esis (Saltman and Gavin, 1985). It may be that the function of 
the type II receptor differs depending on species or type or 
developmental stage of the cell studied. 
We have identified specific Sm/IGF receptors (both type I 
and type II), and possibly insulin receptors, on astroglial cells 
cultured from neonatal rats and have shown that they may 
mediate the mitogenic response of astroglial cells to Sm/IGFs 
and insulin. Our studies indicate that each of the Sm/IGFs, and 
possibly insulin, may have important roles in the regulation of 
brain growth. 
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